NVCR

11.13

3.30% -0.38

Pre-mercato: 11.53 0.40 +3.59%

Novocure Ltd (NVCR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NVCR Giù? Forum Previsione

Precedente Chiudi:

$11.51

Aprire:

$11.6

Volume 24 ore:

1.37M

Relative Volume:

0.88

Capitalizzazione di mercato:

$1.24B

Reddito:

$577.74M

Utile/perdita netta:

$-149.78M

Rapporto P/E:

-7.95

EPS:

-1.4

Flusso di cassa netto:

$-78.21M

1 W Prestazione:

-1.68%

1M Prestazione:

-36.44%

6M Prestazione:

-49.98%

1 anno Prestazione:

-42.30%

Intervallo 1D:

$11.11

$11.69

Intervallo di 1 settimana:

$11.11

$11.94

Portata 52W:

$10.91

$34.13

Novocure Ltd Stock (NVCR) Company Profile

Nome

Novocure Ltd

Settore

Healthcare (1160)

Industria

Medical Devices (149)

Telefono

44 (0)15 3475 6700

Indirizzo

NO. 4 THE FORUM, ST. HELIER

Dipendente

1,488

Cinguettio

@novocure

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

NVCR's Discussions on Twitter

Confronta NVCR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVCR Novocure Ltd	11.13	1.27B	577.74M	-149.78M	-78.21M	-1.40
ABT Abbott Laboratories	134.28	227.88B	43.11B	13.98B	6.78B	7.98
BSX Boston Scientific Corp	103.14	152.55B	18.49B	2.51B	3.23B	1.68
SYK Stryker Corp	377.58	143.34B	23.82B	2.92B	4.02B	7.55
MDT Medtronic Plc	92.88	114.49B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	78.35	46.11B	5.69B	4.14B	577.90M	6.96

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-07-08	Iniziato	Ladenburg Thalmann	Buy
2024-12-02	Aggiornamento	Evercore ISI	In-line → Outperform
2024-10-16	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-28	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-08	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-04	Iniziato	SVB Securities	Outperform
2023-07-31	Aggiornamento	Evercore ISI	Underperform → In-line
2023-06-07	Aggiornamento	Wedbush	Underperform → Neutral
2023-05-16	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2023-01-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-01-05	Reiterato	H.C. Wainwright	Buy
2022-11-29	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-24	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-05	Downgrade	Evercore ISI	In-line → Underperform
2022-05-16	Iniziato	H.C. Wainwright	Buy
2022-02-08	Iniziato	Loop Capital	Buy
2022-02-02	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-20	Aggiornamento	Truist	Hold → Buy
2022-01-03	Aggiornamento	Evercore ISI	Underperform → In-line
2021-07-01	Downgrade	Mizuho	Buy → Neutral
2021-04-14	Downgrade	Wedbush	Neutral → Underperform
2021-01-25	Reiterato	Piper Sandler	Overweight
2020-09-23	Iniziato	Northland Capital	Outperform
2020-09-18	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-17	Downgrade	Truist	Buy → Hold
2020-06-01	Ripresa	Oppenheimer	Perform
2020-05-01	Downgrade	Oppenheimer	Outperform → Perform
2020-04-09	Downgrade	Evercore ISI	In-line → Underperform
2020-03-05	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-07-29	Aggiornamento	SunTrust	Hold → Buy
2019-07-26	Downgrade	JP Morgan	Overweight → Neutral
2019-07-26	Downgrade	Wedbush	Outperform → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2018-11-02	Downgrade	Wells Fargo	Outperform → Market Perform
2018-07-16	Iniziato	Evercore ISI	Outperform
2018-04-18	Reiterato	Mizuho	Buy
2018-02-23	Reiterato	Mizuho	Buy
2017-05-24	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-07-29	Reiterato	Wedbush	Outperform
2016-01-19	Iniziato	Barclays	Underweight
2015-12-02	Iniziato	Deutsche Bank	Hold

Mostra tutto

Novocure Ltd Borsa (NVCR) Ultime notizie

Aug 10, 2025

Statistical indicators supporting NovoCure Limited’s strengthFree High Accuracy Alerts for ROI Traders - Newser

Aug 10, 2025

Aug 09, 2025

NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest

Aug 09, 2025

Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser

Aug 09, 2025

Aug 08, 2025

Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser

Aug 08, 2025

Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser

Aug 08, 2025

Aug 07, 2025

NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks

Aug 07, 2025

Aug 06, 2025

Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser

Aug 06, 2025

Aug 04, 2025

How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser

Aug 04, 2025

Aug 03, 2025

How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News

Aug 03, 2025

What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News

Aug 03, 2025

Aug 02, 2025

How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News

Aug 02, 2025

Aug 01, 2025

Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser

Aug 01, 2025

Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st

Aug 01, 2025

NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st

Aug 01, 2025

NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World

Aug 01, 2025

Jul 31, 2025

Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks

Jul 31, 2025

NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest

Jul 31, 2025

NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha

Jul 31, 2025

Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser

Jul 31, 2025

Jul 30, 2025

Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser

Jul 30, 2025

Why NovoCure Stock Is Cratering Today - Mitrade

Jul 30, 2025

Jul 29, 2025

NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 29, 2025

Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser

Jul 29, 2025

Jul 28, 2025

What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News

Jul 28, 2025

Top 3 Health Care Stocks That May Explode In July - inkl

Jul 28, 2025

Jul 27, 2025

Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World

Jul 27, 2025

NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest

Jul 27, 2025

Jul 26, 2025

NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st

Jul 26, 2025

Jul 25, 2025

NovoCure: Q2 Earnings Snapshot - Norwalk Hour

Jul 25, 2025

NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha

Jul 25, 2025

Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jul 25, 2025

Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus

Jul 25, 2025

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛

Jul 25, 2025

NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional

Jul 25, 2025